# Clinical Efficacy of Doripenem in Treating Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Systematic Review and Meta-Analysis

## Authors

- Kun-Yu Wu ([ORCID](https://orcid.org/0000-0003-4779-0647)) — Department of Radiology, Chi Mei Medical Center, Liouying, Tainan, Taiwan
- Chien-Ming Chao ([ORCID](https://orcid.org/0000-0003-0235-9060)) — Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan
- Guang-Mao Lee ([ORCID](https://orcid.org/0000-0001-9702-7928)) — Department of Nursing, Kaohsiung Municipal United Hospital, Taiwan

## Article information

- **Journal:** The Ulutas Medical Journal (Ulutas Med J), ISSN 2149-388X
- **Issue:** Volume 8, Issue 3 (2022), pages 110–117
- **Article type:** Meta-Analysis
- **Published online:** 2022-09-09
- **DOI:** [10.5455/umj.20220513031721](https://doi.org/10.5455/umj.20220513031721)
- **Licence:** [CC BY-NC 4.0](https://creativecommons.org/licenses/by-nc/4.0/)
- **Article page:** https://www.ulutasmedicaljournal.com/?mno=38410
- **PDF:** https://www.ulutasmedicaljournal.com/pdf/38410.pdf

## Abstract

This meta-analysis investigated whether the clinical efficacy of doripenem is comparable to that of alternative antibiotics for treating hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The PubMed, Web of Science, Cochrane Library, Ovid MEDLINE, and EBSCO databases were searched for literature published before October 20, 2021. Clinical studies comparing the efficacy of doripenem with that of other antibiotics in HAP/VAP treatment were included. Primary outcomes included all-cause mortality at 28 to 30 days, whereas the secondary outcome was the clinical cure rate. In total, 5 clinical studies were included in this meta-analysis. All-cause mortality did not differ significantly between doripenem and the comparators. For VAP alone, no statistical differences were observed between doripenem and the comparators. For Pseudomonas aeruginosa-related pneumonia, mortality did not differ between doripenem and the comparators. The clinical cure rates were 60.7% and 57.3% for doripenem and the comparators, respectively; a similar trend was observed in the subgroup analysis for VAP. For HAP/VAP due to P. aeruginosa, the clinical cure rates for doripenem and the comparators did not differ. Doripenem was comparable to other antibiotics in the treatment of HAP and VAP.

## Keywords

Doripenem; hospital-acquired pneumonia; mortality; Pseudomonas aeruginosa; ventilator-associated pneumonia

## How to cite

Wu KY, Chao CM, Lee GM. Clinical Efficacy of Doripenem in Treating Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Systematic Review and Meta-Analysis. Ulutas Med J. 2022;8(3):110-117. doi:10.5455/umj.20220513031721

## References

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9 https://doi.org/10.1001/jama.2009.1754
2. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370:1198-208 Doripenem for HAP and VAP Wu et al. https://doi.org/10.1056/nejmoa1306801
3. Baker D, Quinn B. Hospital acquired pneumonia prevention Initiative-2: incidence of non-ventilator hospital-acquired pneumonia in the United States. Am J Infect Control 2018; 46:2-7 https://doi.org/10.1016/j.ajic.2017.08.036
4. Zaragoza R, Vidal-Cortés P, Aguilar G, Borges M, Diaz E, Ferrer R, et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care 2020; 24:383 https://doi.org/10.1186/s13054-020-03091-2
5. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS/ ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guideline for the management of hospital-acquired pneumonia (HAP)/ventilator -associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 2017; 50:1700582 https://doi.org/10.1183/13993003.00582-2017
6. Giuliano KK, Baker D, Quinn B. The epidemiology of nonventilator hospital-acquired pneumonia in the United States. Am J Infect Control 2018; 46:322-7 https://doi.org/10.1016/j.ajic.2017.09.005
7. Ibn Saied W, Mourvillier B, Cohen Y, Ruckly S, Reignier J, Marcotte G, et al. A Comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Crit Care Med 2019; 47:345-52 https://doi.org/10.1097/ccm.0000000000003553
8. Micek ST, Chew B, Hampton N, Kollef MH. A Case-control study assessing the impact of nonventilated hospital-acquired pneumonia on patient outcomes. Chest 2016; 150:1008-14 https://doi.org/10.1016/j.chest.2016.04.009
9. Chou CC, Shen CF, Chen SJ, Chen HM, Wang YC, Chang WS, et al. Recommendations and guidelines for the treatment of pneumonia in Taiwan. J Microbiol Immunol Infect 2019; 52:172-99 https://doi.org/10.1016/j.jmii.2018.11.004
10. Wu H, Harder C, Culley C. The 2016 Clinical practice guidelines for management of hospital-acquired and ventilator-associated pneumonia. Can J Hosp Pharm 2017; 70:251-2 https://doi.org/10.4212/cjhp.v70i3.1667
11. Tsai WC, Syue LS, Ko WC, Lo CL, Lee NY. Antimicrobial treatment of monomicrobial phenotypic carbapenem-resistant Klebsiella pneumoniae bacteremia: Two are better than one. J Microbiol Immunol Infect 2021 Oct 1;S1684-1182(21)00188-2 https://doi.org/10.1016/j.jmii.2021.09.002
12. Jean SS, Lee YL, Liu PY, Lu MC, Ko WC, Hsueh PR. Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018. J Microbiol Immunol Infect 2021 Sep 3;S1684-1182 (21)00182-1 https://doi.org/10.1016/j.jmii.2021.07.015
13. Jean SS, Lee WS, Ko WC, Hsueh PR. In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018. J Microbiol Immunol Infect 2021; 54:627-31 https://doi.org/10.1016/j.jmii.2020.04.017
14. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089-96 https://doi.org/10.1097/ccm.0b013e3181691b99
15. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16:R218 https://doi.org/10.1186/cc11862
16. Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24:2113-26 https://doi.org/10.1185/03007990802179255
17. Luyt CE, Aubry A, Lu Q, Micaelo M, Bréchot N, Brossier F, et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58:1372-80 https://doi.org/10.1128/aac.02109-13
18. Liu WD, Shih MC, Chuang YC, Wang JT, Sheng WH. Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia. J Microbiol Immunol Infect 2019; 52:788-95 https://doi.org/10.1016/j.jmii.2019.04.008
19. Tang HJ, Lai CC. Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia. Lancet Infect Dis 2020; 20:20 https://doi.org/10.1016/s1473-3099(19)30693-0
20. U.S. Food and Drug Administration. https://www.fda.gov/ drugs/drug-safety-and-availability/fda-drug-safety-commu nication-fda-approves-label-changes-antibacterial-doribax-doripenem-describing. Accessed on October 26, 2021
21. Chao CM, Chen CC, Huang HL, Chuang YC, Lai CC, Tang HJ. Clinical experience of patients receiving doripenem-containing regimens for the treatment of healthcare-associated infections. PLoS One 2016;11: e0167522 https://doi.org/10.1371/journal.pone.0167522
22. Mustafa M, Chan WM, Lee C, Harijanto E, Loo CM, Van Kinh N, et al. A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD). Int J Antimicrob Agents 2014; 43:353-60 https://doi.org/10.1016/j.ijantimicag.2014.01.017
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151:W65-94 https://doi.org/10.7326/0003-4819-151-4-200908180-00136
24. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928 https://doi.org/10.1136/bmj.d5928
25. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in meta-analyses. Eur J Epidemiol 2010; 25:603-5 https://doi.org/10.1007/s10654-010-9491-z
26. Lai CC, Cheng IL, Chen YH, Tang HJ. The efficacy and safety of doripenem in the treatment of acute bacterial infections-Doripenem for HAP and VAP Wu et al. A systemic review and meta-analysis of randomized controlled trials. J Clin Med 2019; 8:958 https://doi.org/10.3390/jcm8070958
27. Gales AC, Azevedo HD, Cereda RF, Girardello R, Xavier DE. Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study. Braz J Infect Dis 2011; 15:513-20 https://doi.org/10.1590/s1413-86702011000600003
28. Betriu C, Gómez M, López-Fabal F, Culebras E, Rodríguez-Avial I, Picazo JJ. Activity of doripenem against extended-spectrum betalactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates. Eur J Clin Microbiol Infect Dis 2010; 29:1179-81 https://doi.org/10.1007/s10096-010-0974-3
29. Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009; 63:426-33 https://doi.org/10.1016/j.diagmicrobio.2009.01.026
30. Christiansen KJ, Ip M, Ker HB, Mendoza M, Hsu L, Kiratisin P, et al. In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study. Int J Antimicrob Agents 2010; 36:501-6 https://doi.org/10.1016/j.ijantimicag.2010.08.002
31. Fera MT, Zummo S, A DES. In vitro activity studies of doripenem and two other carbapenems tested against Pseudomonas aeruginosa and other non-fermentative bacilli. J Chemother 2011; 23:335-40
32. Fujimura T, Anan N, Sugimori G, Watanabe T, Jinushi Y, Yoshida I, et al. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int J Antimicrob Agents 2009; 34:523-8 https://doi.org/10.1016/j.ijantimicag.2009.07.008
33. Redman R, File TM, Jr. Safety of intravenous infusion of doripenem. Clin Infect Dis 2009;49 Suppl 1: S28-35 https://doi.org/10.1086/599813